Literature DB >> 11314741

Relationships between cortisol, dehydroepiandrosterone sulphate and insulin-like growth factor-I system in dementia.

G Murialdo1, A Barreca, F Nobili, A Rollero, G Timossi, M V Gianelli, F Copello, G Rodriguez, A Polleri.   

Abstract

Changes in the hypothalamus-pituitary-adrenal axis (HPAA) function, entailing elevated cortisol circulating titres, occur in aging and in some neurological conditions, such as Alzheimer's disease (AD). Excess cortisol has neurotoxic effects which affect hippocampal neurones. Dehydroepiandrosterone sulphate (DHEAS) has an antiglucocorticoid activity and neuroprotective effects, but its levels decrease with aging. Glucocorticoids influence the production of insulin-like growth factor-I (IGF-I) and modify its systemic and neurotrophic biological activity by inducing changes in IGF-binding proteins (IGFBPs). We looked for relationships between cortisol, DHEAS levels, and IGF-I - IGFBPs system in AD. Cortisol, DHEAS and GH levels at 02:00, 08:00, 14:00, 20:00 h, basal IGF-I, IGFBP-1 and IGFBP-3 levels were determined by RIAs or IRMA in 25 AD patients, aged 58-89 yr, and in 12 age-matched healthy controls. AD subjects had higher cortisol, lower DHEAS levels and increased cortisol/DHEAS ratio (C/Dr) than controls. In AD cases, total IGF-I, IGFBP-3, and IGF-I/IGFBP ratios were significantly lowered, while IGFBP-1 levels were significantly higher than in controls. We found a significant inverse correlation between IGF-I and IGFBP-3 levels vs C/Dr, and between both IGF-I/IGFBPs ratios vs mean cortisol levels. IGFBP-3 correlated directly with DHEAS. Cortisol was directly and IGF-I inversely correlated with cognitive impairment. In AD patients we found that alterations in HPAA function and elevated C/Dr are related to lowered total and free IGF-I levels. These findings and their relationship to cognitive impairment suggest that changes in hormonal set-up might influence the clinical presentation of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314741     DOI: 10.1007/BF03343833

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  48 in total

Review 1.  Insulin-like growth factors as mediators of functional plasticity in the adult brain.

Authors:  I Torres-Aleman
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

Review 2.  Stress and the aging hippocampus.

Authors:  B S McEwen
Journal:  Front Neuroendocrinol       Date:  1999-01       Impact factor: 8.606

3.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

Review 4.  Functional consequences of the somatopause and its treatment.

Authors:  A R Hoffman; S A Lieberman; G Butterfield; J Thompson; R L Hintz; G P Ceda; R Marcus
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.925

Review 5.  Brain corticosteroid receptor balance in health and disease.

Authors:  E R De Kloet; E Vreugdenhil; M S Oitzl; M Joëls
Journal:  Endocr Rev       Date:  1998-06       Impact factor: 19.871

6.  The Global Deterioration Scale for assessment of primary degenerative dementia.

Authors:  B Reisberg; S H Ferris; M J de Leon; T Crook
Journal:  Am J Psychiatry       Date:  1982-09       Impact factor: 18.112

7.  A prospective study on cortisol, dehydroepiandrosterone sulfate, and cognitive function in the elderly.

Authors:  S Kalmijn; L J Launer; R P Stolk; F H de Jong; H A Pols; A Hofman; M M Breteler; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

8.  Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy.

Authors:  M J de Leon; T McRae; J R Tsai; A E George; D L Marcus; M Freedman; A P Wolf; B McEwen
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

9.  Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease.

Authors:  M Hatzinger; A Z'Brun; U Hemmeter; E Seifritz; F Baumann; E Holsboer-Trachsler; I J Heuser
Journal:  Neurobiol Aging       Date:  1995 Mar-Apr       Impact factor: 4.673

10.  Serum dehydroepiandrosterone sulfate in Alzheimer's disease and in multi-infarct dementia.

Authors:  B Näsman; T Olsson; T Bäckström; S Eriksson; K Grankvist; M Viitanen; G Bucht
Journal:  Biol Psychiatry       Date:  1991-10-01       Impact factor: 13.382

View more
  19 in total

Review 1.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

Review 2.  Neurosteroids: endogenous role in the human brain and therapeutic potentials.

Authors:  Doodipala Samba Reddy
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 3.  Dementia: a neuroendocrine perspective.

Authors:  A Polleri; M V Gianelli; G Murialdo
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

4.  Circulating insulin-like growth factor 1 and insulin-like growth factor binding protein-3 level in Alzheimer's disease: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2016-07-05       Impact factor: 3.307

Review 5.  Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging.

Authors:  J Eric Ahlskog; Yonas E Geda; Neill R Graff-Radford; Ronald C Petersen
Journal:  Mayo Clin Proc       Date:  2011-09       Impact factor: 7.616

6.  Insulin and IGF-I prevent brain atrophy and DNA loss in diabetes.

Authors:  Predrag Serbedzija; James E Madl; Douglas N Ishii
Journal:  Brain Res       Date:  2009-09-23       Impact factor: 3.252

Review 7.  Estrogen and Alzheimer's disease: the story so far.

Authors:  Brenna Cholerton; Carey E Gleason; Laura D Baker; Sanjay Asthana
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

9.  Insulin-like growth factor I and the pathogenesis of delirium: a review of current evidence.

Authors:  Dimitrios Adamis; David Meagher
Journal:  J Aging Res       Date:  2011-07-03

10.  Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats.

Authors:  Predrag Serbedžija; Douglas N Ishii
Journal:  Indian J Endocrinol Metab       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.